TrialPath
Recruiting

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002 · AstraZeneca
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomized, Double-Blind, Placebo-Controlled, 2-Cohort, Phase III Study of Saruparib Combined With Physician's Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone-Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA-directed 177Lutetium-Containing Therapy Without Disease Progression, and With Prostate-Specific Antigen ≥ 0.2 ng/mL: EvoPAR-Prostate05
About this study
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
Eligibility criteria
Inclusion Criteria: * Participant must be ≥ 18 at the time of signing the informed consent. * Histologically documented diagnosis of prostate adenocarcinoma that is de novo or recurrent and hormone-sensitive. * Metastatic disease confirmed prior to initiation of previous treatment with docetaxel or Lu-PSMA-containing regimens for mHSPC. * Previous treatment with docetaxel (IV, Q3w)- or Lu-PSMA (IV, Q6w) with last dose within past 6 months. * Participants must have the following: * Must be receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy. * Had no evidence of disease progression * Had all toxicities related to docetaxel- or Lu-PSMA-containing treatment (except for alopecia and peripheral neuropathy) resolved to CTCAE Grade 1 or lower. * PSA ≥ 0.2 ng/mL within 14 days prior to randomization. * Serum testosterone \< 1.7 nmol/L or 50 ng/dL. * Palliative radiotherapy for symptoms management will be permitted and is to be completed at least 4 weeks prior to randomization for wide field radiation therapy and at least 2 weeks prior to randomization for limited field radiation therapy. * Provision of a FFPE tumor tissue sample and a blood sample (for ctDNA). * Confirmed HRRm, HRD and PTEN status. * Adequate organ and bone marrow function. * Minimum life expectancy of 6 months. * Male, assigned at birth, inclusive of all gender identities. * Contraceptive use by participants or participant partners should be consistent with local regulations. * Capable of giving signed informed consent. * \- - Exclusion Criteria: * Hypersensitivity to saruparib, ARPI or any excipients of these products or any contraindication or restriction based on the local label. * Any history of persisting (\> 2 weeks) severe cytopenia due to any cause (eg, ANC\< 0.5 × 10\^9/L or platelets \< 50 × 10\^9/L) * Any known predisposition to bleeding (eg, active peptic ulceration, recent \[within6 months\] hemorrhagic stroke, proliferative diabetic retinopathy. * Spinal cord compression or brain metastases unless asymptomatic and stable. * History of MDS/AML or with features suggestive of MDS/AML * History of another primary malignancy, with some exceptions. * Any chronic gastrointestinal diseases or conditions including inability to swallow the formulated product that would preclude adequate absorption of any study drug. * History of seizure or predispose to seizure, including any history of loss of consciousness or transient ischemic attack within 12 months of enrolment. * Serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. * Major surgical procedure or significant traumatic injury within 4 weeks of the first dose or an anticipated need for major surgery during the study. * Switched ARPI agent in previous treatment for mHSPC due to disease progression. Note: if the ARPI agent was switched due to any reason other than disease progression and switch was prior to ICF signature, participants will be eligible. * Any prior treatment with a PARPi or platinum chemotherapy. * \- -
Study design
Enrollment target: 1330 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-09-15
Estimated completion: 2033-05-27
Last updated: 2026-10-15
Interventions
Drug: SaruparibOther: PlaceboDrug: EnzalutamideDrug: DarolutamideDrug: Abiraterone
Primary outcomes
  • • Radiographic progression-free survival (rPFS) (Up to approximately 56 months)
Sponsor
AstraZeneca · industry
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · 1-877-240-9479
All locations (210)
Research SiteNot Yet Recruiting
Hot Springs, Arkansas, United States
Research SiteRecruiting
Springdale, Arkansas, United States
Research SiteNot Yet Recruiting
Beverly Hills, California, United States
Research SiteNot Yet Recruiting
Los Alamitos, California, United States
Research SiteNot Yet Recruiting
Los Angeles, California, United States
Research SiteWithdrawn
San Diego, California, United States
Research SiteRecruiting
Margate, Florida, United States
Research SiteRecruiting
Miami, Florida, United States
Research SiteNot Yet Recruiting
Orlando, Florida, United States
Research SiteNot Yet Recruiting
Honolulu, Hawaii, United States
Research SiteNot Yet Recruiting
Chicago, Illinois, United States
Research SiteNot Yet Recruiting
Chicago, Illinois, United States
Research SiteNot Yet Recruiting
Elk Grove Village, Illinois, United States
Research SiteNot Yet Recruiting
Hinsdale, Illinois, United States
Research SiteNot Yet Recruiting
Ames, Iowa, United States
Research SiteNot Yet Recruiting
Baltimore, Maryland, United States
Research SiteNot Yet Recruiting
Baltimore, Maryland, United States
Research SiteNot Yet Recruiting
Towson, Maryland, United States
Research SiteNot Yet Recruiting
Detroit, Michigan, United States
Research SiteNot Yet Recruiting
Grand Rapids, Michigan, United States
Research SiteNot Yet Recruiting
Marshall, Minnesota, United States
Research SiteNot Yet Recruiting
Camden, New Jersey, United States
Research SiteNot Yet Recruiting
Albuquerque, New Mexico, United States
Research SiteNot Yet Recruiting
Shirley, New York, United States
Research SiteNot Yet Recruiting
Canton, Ohio, United States
Research SiteNot Yet Recruiting
Cincinnati, Ohio, United States
Research SiteNot Yet Recruiting
Portland, Oregon, United States
Research SiteNot Yet Recruiting
Portland, Oregon, United States
Research SiteNot Yet Recruiting
Greenville, South Carolina, United States
Research SiteNot Yet Recruiting
Aberdeen, South Dakota, United States
Research SiteNot Yet Recruiting
Mitchell, South Dakota, United States
Research SiteNot Yet Recruiting
Pierre, South Dakota, United States
Research SiteNot Yet Recruiting
Sioux Falls, South Dakota, United States
Research SiteNot Yet Recruiting
Yankton, South Dakota, United States
Research SiteNot Yet Recruiting
Nashville, Tennessee, United States
Research SiteNot Yet Recruiting
Austin, Texas, United States
Research SiteNot Yet Recruiting
Dallas, Texas, United States
Research SiteNot Yet Recruiting
Fort Worth, Texas, United States
Research SiteNot Yet Recruiting
Longview, Texas, United States
Research SiteNot Yet Recruiting
Wichita Falls, Texas, United States
Research SiteWithdrawn
Salt Lake City, Utah, United States
Research SiteNot Yet Recruiting
Spokane, Washington, United States
Research SiteNot Yet Recruiting
Graz, Austria
Research SiteNot Yet Recruiting
Linz, Austria
Research SiteNot Yet Recruiting
Salzburg, Austria
Research SiteNot Yet Recruiting
Vienna, Austria
Research SiteNot Yet Recruiting
Barretos, Brazil
Research SiteNot Yet Recruiting
Brasília, Brazil
Research SiteNot Yet Recruiting
Natal, Brazil
Research SiteNot Yet Recruiting
Porto Alegre, Brazil
Research SiteNot Yet Recruiting
São Caetano do Sul, Brazil
Research SiteNot Yet Recruiting
São Paulo, Brazil
Research SiteNot Yet Recruiting
São Paulo, Brazil
Research SiteNot Yet Recruiting
Calgary, Alberta, Canada
Research SiteNot Yet Recruiting
Edmonton, Alberta, Canada
Research SiteNot Yet Recruiting
Abbotsford British Columbia, British Columbia, Canada
Research SiteNot Yet Recruiting
Brampton, Ontario, Canada
Research SiteNot Yet Recruiting
Kitchener, Ontario, Canada
Research SiteNot Yet Recruiting
North York, Ontario, Canada
Research SiteNot Yet Recruiting
Ottawa, Ontario, Canada
Research SiteNot Yet Recruiting
Toronto, Ontario, Canada
Research SiteNot Yet Recruiting
Windsor, Ontario, Canada
Research SiteNot Yet Recruiting
Greenfield Park, Quebec, Canada
Research SiteRecruiting
Montreal, Quebec, Canada
Research SiteNot Yet Recruiting
Montreal, Quebec, Canada
Research SiteNot Yet Recruiting
Saint-Jérôme, Quebec, Canada
Research SiteNot Yet Recruiting
Saskatoon, Saskatchewan, Canada
Research SiteNot Yet Recruiting
Beijing, China
Research SiteNot Yet Recruiting
Changsha, China
Research SiteNot Yet Recruiting
Chengdu, China
Research SiteNot Yet Recruiting
Chengdu, China
Research SiteNot Yet Recruiting
Chongqing, China
Research SiteNot Yet Recruiting
Fuzhou, China
Research SiteNot Yet Recruiting
Guangzhou, China
Research SiteNot Yet Recruiting
Guangzhou, China
Research SiteNot Yet Recruiting
Guiyang, China
Research SiteNot Yet Recruiting
Jiaxing, China
Research SiteNot Yet Recruiting
Jinan, China
Research SiteNot Yet Recruiting
Kunming, China
Research SiteNot Yet Recruiting
Kunming, China
Research SiteNot Yet Recruiting
Lanzhou, China
Research SiteNot Yet Recruiting
Nanchang, China
Research SiteNot Yet Recruiting
Nanjing, China
Research SiteNot Yet Recruiting
Nantong, China
Research SiteNot Yet Recruiting
Ningbo, China
Research SiteNot Yet Recruiting
Qingdao, China
Research SiteNot Yet Recruiting
Shandong, China
Research SiteNot Yet Recruiting
Shanghai, China
Research SiteNot Yet Recruiting
Shanghai, China
Research SiteNot Yet Recruiting
Wenzhou, China
Research SiteNot Yet Recruiting
Wuhan, China
Research SiteNot Yet Recruiting
Wuhan, China
Research SiteNot Yet Recruiting
Wuhan, China
Research SiteNot Yet Recruiting
Xi'an, China
Research SiteNot Yet Recruiting
Angers, France
Research SiteNot Yet Recruiting
Caen, France
Research SiteNot Yet Recruiting
Montpellier, France
Research SiteNot Yet Recruiting
Paris, France
Research SiteNot Yet Recruiting
Poitiers, France
Research SiteNot Yet Recruiting
Bergisch Gladbach, Germany
Research SiteNot Yet Recruiting
Berlin, Germany
Research SiteNot Yet Recruiting
Berlin, Germany
Research SiteNot Yet Recruiting
Bonn, Germany
Research SiteNot Yet Recruiting
Cologne, Germany
Research SiteNot Yet Recruiting
Dresden, Germany
Research SiteNot Yet Recruiting
Duisburg, Germany
Research SiteNot Yet Recruiting
Essen, Germany
Research SiteNot Yet Recruiting
Frankfurt am Main, Germany
Research SiteNot Yet Recruiting
Göttingen, Germany
Research SiteNot Yet Recruiting
Hamburg, Germany
Research SiteNot Yet Recruiting
Heidelberg, Germany
Research SiteNot Yet Recruiting
Herne, Germany
Research SiteNot Yet Recruiting
Mannheim, Germany
Research SiteNot Yet Recruiting
Marburg, Germany
Research SiteNot Yet Recruiting
Mettmann, Germany
Research SiteNot Yet Recruiting
München, Germany
Research SiteNot Yet Recruiting
Münster, Germany
Research SiteNot Yet Recruiting
Nuremberg, Germany
Research SiteNot Yet Recruiting
Nürtingen, Germany
Research SiteNot Yet Recruiting
Rostock, Germany
Research SiteNot Yet Recruiting
Stuttgart, Germany
Research SiteNot Yet Recruiting
Ulm, Germany
Research SiteNot Yet Recruiting
Würzburg, Germany
Research SiteNot Yet Recruiting
Hong Kong, Hong Kong
Research SiteNot Yet Recruiting
Hong Kong, Hong Kong
Research SiteNot Yet Recruiting
Budapest, Hungary
Research SiteNot Yet Recruiting
Budapest, Hungary
Research SiteNot Yet Recruiting
Budapest, Hungary
Research SiteNot Yet Recruiting
Pécs, Hungary
Research SiteNot Yet Recruiting
Szeged, Hungary
Research SiteNot Yet Recruiting
Ansārinagar, India
Research SiteNot Yet Recruiting
Bangalore, India
Research SiteNot Yet Recruiting
Delhi, India
Research SiteNot Yet Recruiting
Kannur, India
Research SiteNot Yet Recruiting
Nagpur, India
Research SiteNot Yet Recruiting
New Delhi, India
Research SiteNot Yet Recruiting
Vadodara, India
Research SiteNot Yet Recruiting
Bari, Italy
Research SiteNot Yet Recruiting
Genova, Italy
Research SiteNot Yet Recruiting
Padova, Italy
Research SiteNot Yet Recruiting
Rozzano, Italy
Research SiteNot Yet Recruiting
Chiba, Japan
Research SiteNot Yet Recruiting
Fukuoka, Japan
Research SiteNot Yet Recruiting
Fukuoka, Japan
Research SiteNot Yet Recruiting
Hiroshima, Japan
Research SiteNot Yet Recruiting
Kamakura-shi, Japan
Research SiteNot Yet Recruiting
Kawagoe-shi, Japan
Research SiteNot Yet Recruiting
Kisarazu-shi, Japan
Research SiteNot Yet Recruiting
Kita-gun, Japan
Research SiteNot Yet Recruiting
Kobe, Japan
Research SiteNot Yet Recruiting
Kumamoto, Japan
Research SiteNot Yet Recruiting
Maebashi, Japan
Research SiteNot Yet Recruiting
Nagano, Japan
Research SiteNot Yet Recruiting
Nagasaki, Japan
Research SiteNot Yet Recruiting
Nagoya, Japan
Research SiteNot Yet Recruiting
Nagoya, Japan
Research SiteNot Yet Recruiting
Osaka, Japan
Research SiteNot Yet Recruiting
Sakai, Japan
Research SiteNot Yet Recruiting
Sakura-shi, Japan
Research SiteNot Yet Recruiting
Sapporo, Japan
Research SiteNot Yet Recruiting
Suita-shi, Japan
Research SiteNot Yet Recruiting
Yokohama, Japan
Research SiteNot Yet Recruiting
Gdansk, Poland
Research SiteNot Yet Recruiting
Koszalin, Poland
Research SiteNot Yet Recruiting
Krakow, Poland
Research SiteNot Yet Recruiting
Lodz, Poland
Research SiteNot Yet Recruiting
Olsztyn, Poland
Research SiteNot Yet Recruiting
Poznan, Poland
Research SiteNot Yet Recruiting
Warsaw, Poland
Research SiteNot Yet Recruiting
Wroclaw, Poland
Research SiteNot Yet Recruiting
Rio Piedras, Puerto Rico
Research SiteRecruiting
Daegu, South Korea
Research SiteNot Yet Recruiting
Goyang-si, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Barcelona, Spain
Research SiteNot Yet Recruiting
Barcelona, Spain
Research SiteNot Yet Recruiting
Córdoba, Spain
Research SiteNot Yet Recruiting
Las Palmas de Gran Canaria, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Santander, Spain
Research SiteNot Yet Recruiting
Valencia, Spain
Research SiteNot Yet Recruiting
Aarau, Switzerland
Research SiteNot Yet Recruiting
Chur, Switzerland
Research SiteNot Yet Recruiting
Kaohsiung City, Taiwan
Research SiteWithdrawn
Taichung, Taiwan
Research SiteRecruiting
Tainan, Taiwan
Research SiteNot Yet Recruiting
Taipei, Taiwan
Research SiteNot Yet Recruiting
Taipei, Taiwan
Research SiteNot Yet Recruiting
Taoyuan, Taiwan
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Khlong Luang, Thailand
Research SiteNot Yet Recruiting
Songkhla, Thailand
Research SiteNot Yet Recruiting
Adana, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Ankara, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Ankara, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Cordaleo, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Istanbul, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Izmir, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Cambridge, United Kingdom
Research SiteNot Yet Recruiting
Glasgow, United Kingdom
Research SiteNot Yet Recruiting
London, United Kingdom
Research SiteNot Yet Recruiting
London, United Kingdom
Research SiteNot Yet Recruiting
Manchester, United Kingdom
Research SiteNot Yet Recruiting
Plymouth, United Kingdom